We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Agile Therapeutics Inc (AGRX) USD0.0001

Sell:$0.62 Buy:$0.63 Change: $0.52 (45.03%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Change: $0.52 (45.03%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Change: $0.52 (45.03%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. The Company’s sole approved product, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive. Twirla is a method of contraception for use in women of reproductive potential for whom a combined hormonal contraceptive is appropriate. Twirla is a prescription combined hormonal contraceptive patch, which contains the active ingredients ethinyl estradiol (EE), which is a synthetic estrogen and levonorgestrel (LNG), which is a type of progestin. Twirla delivers 30 micrograms of EE per day, a dose of EE consistent with the dose delivered by many commonly prescribed oral contraceptives. The Company commercializes Twirla in the United States. Twirla leverages the Company’s transdermal patch technology called Skinfusion. Skinfusion is designed to allow drug delivery through the skin while optimizing patch adhesion and patient comfort and wearability.

Contact details

500 College Road East
United States
+1 (609) 6831880

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$6.99 million
Shares in issue:
4.54 million
United States
US dollar

Key personnel

  • Alfred Altomari
    Chairman of the Board, Chief Executive Officer
  • Jason Butch
    Principal Financial Officer
  • Geoffrey Gilmore
    Senior Vice President, General Counsel, Corporate Secretary
  • Robert Conway
    Senior Vice President and Chief Supply Chain Officer
  • Paul Korner
    Senior Vice President, Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.